Figure 2.

MAGL inhibitor JZL184 reduces infarct volume and improves neurologic deficits after permanent ischemic stroke. A, Basic experimental scheme of permanent MCAO model with a distal MCA electrocoagulation. JZL184 (16 mg/kg) or vehicle was administered i.p. 1 h after induction of ischemia and all read-out parameters were evaluated on day 1 after permanent occlusion of distal MCA. Representative T2-weighted MR images show smaller infarct size in JZL184-treated SHR than in vehicle-treated SHR. Representative thionin-stained coronal sections. Quantification of infarct volume. The neurological deficit was significantly decreased in JZL184-treated SHR. Data are expressed as mean ± SEM (n = 5/group). **P < 0.01 versus vehicle, unpaired t-test. B, Basic experimental scheme of transient MCAO. JZL184 (16 mg/kg, i.p.) or vehicle was administered immediately after reperfusion and all read-out parameters were evaluated on day 1 after transient MCAO. T2-weighted coronal MR images show extensive hyperintense ischemic lesions in the cortex and subcortical area at 1 d after transient MCAO in vehicle- or JZL184-treated SHR. Representative TTC-stained coronal slices. Infarct volume and neurological deficit were unchanged in JZL184-treated SHR. Data are expressed as mean ± SEM (n = 6/group).